In this regard, the SASP can be a double-edged sword in cancer treatment, as it is required by immune cells to mediate antitumor responses [27,28,29] promoting “senescence surveillance” and preventing tumor initiation [30,31], and at chronic levels and pathological conditions such as established tumors, SASP components, such as vascular endothelial growth factor (VEGF), CCL5, and IL-6, can induce cancer, drug resistance, cancer progression, and associated side effects such as cachexia [20,32,33,34,35,36,37,38,39,40,41]. This evidence concerns the gene VEGFA and cancer.